Last reviewed · How we verify
Piperacillin/tazobactam or temocillin
Piperacillin/tazobactam and temocillin are beta-lactam antibiotics that inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins, with tazobactam providing beta-lactamase inhibition to overcome resistance.
Piperacillin/tazobactam and temocillin are beta-lactam antibiotics that inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins, with tazobactam providing beta-lactamase inhibition to overcome resistance. Used for Serious gram-negative and gram-positive bacterial infections (piperacillin/tazobactam), Aerobic gram-negative infections including Enterobacteriaceae (temocillin), Hospital-acquired and nosocomial infections.
At a glance
| Generic name | Piperacillin/tazobactam or temocillin |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Beta-lactam antibiotic / Beta-lactamase inhibitor combination (piperacillin/tazobactam); Beta-lactam antibiotic (temocillin) |
| Target | Penicillin-binding proteins (PBPs); bacterial cell wall peptidoglycan |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Piperacillin is an extended-spectrum penicillin that disrupts peptidoglycan cross-linking in bacterial cell walls, while tazobactam is a beta-lactamase inhibitor that protects piperacillin from enzymatic degradation by resistant organisms. Temocillin is a beta-methoxy-substituted penicillin with intrinsic resistance to many beta-lactamases. These agents are used to treat serious gram-negative and gram-positive bacterial infections.
Approved indications
- Serious gram-negative and gram-positive bacterial infections (piperacillin/tazobactam)
- Aerobic gram-negative infections including Enterobacteriaceae (temocillin)
- Hospital-acquired and nosocomial infections
Common side effects
- Diarrhea
- Nausea
- Rash
- Phlebitis at injection site
- Headache
- Clostridium difficile-associated diarrhea
Key clinical trials
- Antibiotic Dosing in Geriatric Patients At the Emergency Department
- Piperacillin-tazobactam and Temocillin as Carbapenem-alternatives for the Treatment of Severe Infections Due to Extended-spectrum Beta-lactamase-Producing Gram-negative Enterobacteriaceae in the Intensive Care Unit (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: